Vedder Thinking | News Deborah Lu Quoted in Recent Life Sciences Law & Industry Report
Deborah L. Lu, Ph.D., a Shareholder in the New York office of Vedder Price and a member of the firm’s Intellectual Property group, was quoted in a Bloomberg BNA Life Sciences Law & Industry Report article titled “Gene, Method Patent Rulings Said Top Issues for Life Sciences This Year.”
For its first issue of 2013, Life Sciences Law & Industry Report asked attorneys, professionals on its editorial advisory board and other experts, including those from the United Kingdom, Canada, and Japan, to predict the top issues for 2013. They indicated that the focus of the life sciences industry in 2013 will be on patentable subject matter in the United States and Europe, the scope of the patent infringement “safe harbor” provision and “patent exhaustion.”
Of those contributing to this article, a majority ranked the upcoming decision in Association for Molecular Pathology v. Patent and Trademark Office, commonly referred to as the Myriad case, as the top issue. Dr. Lu weighed in, saying, “I think the Supreme Court certified the wrong question: the subject matter should have been isolated genes. By inserting the word ‘human,’ the court appears to be trying to feed into public perception, and perhaps public paranoia, that anything human should not be patentable.” In the article, Dr. Lu also comments on the Mayo v. Prometheus and Bowman v. Monsanto rulings from 2012.
To read the complete Life Sciences Law & Industry Report, please download the attachment below.
Reproduced with permission from Life Sciences Law & Industry Report, 7 LSLR 63 (Jan. 11, 2013). Copyright 2013 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com